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ABSTRACT
A phase 1 dose-escalation trial assessed the chemotherapeutic potential of ammonium perfluorooctanoate (APFO). Forty-nine
primarily solid-tumor cancer patients who failed standard therapy received weekly APFO doses (50–1200 mg) for 6 weeks.
Clinical chemistries and plasma PFOA (anionic APFO) were measured predose and weekly thereafter. Several clinical measures
including total cholesterol, high-density lipoproteins (HDLs), thyroid stimulating hormone (TSH), and free thyroxine (fT4),
relative to PFOA concentrations were examined by: Standard statistical analyses using generalized estimating equations (GEE)
and a probabilistic analysis using probability distribution functions (pdf) at various PFOA concentrations; and a 2-compartment
pharmacokinetic/pharmacodynamic (PK/PD) model to directly estimate mean changes. Based on the GEE, the average rates of
change in total cholesterol and fT4 associated with increasing PFOA were approximately 1.2103mmol/l/lM and
2.8103pmol/l/lM, respectively. The PK/PD model predicted more closely the trends observed in the data as well as the pdfs of
biomarkers. A decline in total cholesterol was observed, with a clear transition in shape and range of the pdfs, manifested by the
maximum value of the Kullback-Leibler (KL) divergence, that occurred at plasma PFOA between 420 and 565lM (175 000–
230 000 ng/ml). High-density lipoprotein was unchanged. An increase in fT4 was observed at a higher PFOA transition point,
albeit TSH was unchanged. Our findings are consistent with some animal models and may motivate re-examination of the
epidemiologic studies to PFOA at levels several orders of magnitude lower than this study. These observational studies have
reported contrary associations, but currently understood biology does not support the existence of such conflicting effects.
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The ammonium salt of perfluorooctanoate (APFO, NHþ4
C7F15COO
-) was used for decades in industrial applications as an
emulsifier in fluoropolymer manufacturing, including the poly-
merization of tetrafluoroethylene (PTFE; Buck et al., 2011). Due
to the environmental and toxicologic concerns, the industrial
use of APFO has been phased-out in the United States (US EPA,
2006).
Ammonium perfluorooctanoate is absorbed orally (Kennedy
et al., 2004), readily dissociates to perfluorooctanoate (herein
also referred to as PFOA) in the blood, and binds to serum pro-
tein. PFOA does not metabolize and is excreted in urine and fe-
ces. Urinary elimination rates vary among the
perfluorocarboxylate homologs and renal tubular secretion and
reabsorption depends on sex, species, and chain-length. For
PFOA, serum elimination half-life values range from hours/days
(rats), weeks (mice), or months (monkeys) (Butenhoff et al., 2004;
Han et al., 2012; Lou et al., 2009), whereas in humans it ranges
between 2.3 and 3.5 years (Bartell et al., 2009; Olsen et al., 2007a;
Russell et al., 2015). Serum PFOA concentrations have declined
in the United States general population between 2000 and 2015
(Olsen et al., 2017).
Although APFO is not genotoxic (Butenhoff et al., 2014),
chronic bioassays in Sprague Dawley rats with dietary adminis-
tration of APFO (up to 300 ppm) resulted in hepatic and pancre-
atic acinar cell adenomas (Biegel et al., 2001) or a proliferative
response in the acinar pancreas (Butenhoff et al., 2012a; Caverly
Rae et al., 2014). Both studies also reported an increase in Leydig
cell adenomas. Various levels of confidence regarding the mode
of action for these 3 tumors have been attributed to activation
of the xenosensor nuclear receptor peroxisome proliferator-
activated receptor a (PPARa) (Klaunig et al., 2012). Weight of evi-
dence indicates that the mode of action steps for liver tumors is
not likely relevant to humans (Gonzalez et al., 1998; Rosen et al.,
2009; US EPA, 2003); whereas a similar PPARa-mediated mode of
action was considered plausible for pancreatic tumors (Klaunig
et al., 2012). Although the prevalence of Leydig cell tumors is low
in humans (0.00004%) compared with the occurrence in Sprague
Dawley rats (5.3%) (Cook et al., 1999), the increased incidence of
such tumor type in rats with exposure to APFO and its relevance
to humans remains recondite.
Occupational epidemiology studies have reported inconsis-
tent associations between PFOA and kidney cancer that may
have been confounded by other workplace exposures (Consonni
et al., 2013; Raleigh et al., 2014; Steenland and Woskie, 2012). A
study of a mid-Ohio river valley community and worker popula-
tion (n¼ 32 254), exposed to drinking water containing PFOA
from an industrial source, reported a significant trend for testic-
ular cancer (17 cases) with a nonsignificant trend observed for
kidney cancer (105 cases) (Barry et al., 2013). The International
Agency for Research on Cancer (IARC) categorized PFOA as a
possible human carcinogen for testicular and kidney cancer
(group 2B) (Benbrahim-Tallaa et al., 2014).
In light of this IARC qualitative hazard index listing and the
presence of PFOA in the general population, it is highly unusual
that an environmental toxicant such as PFOA would ever be
considered for its chemotherapeutic properties. Interestingly,
PFOA has been shown to cause endoplasmic reticulum stress in
tumor cells, activity against PIM kinases, and activity in 5 xeno-
graft models of solid tumors (Barnett et al., 2010). Because PIM
kinases can be overexpressed in many cancers that involve cell
survival, cell cycle progression, and cell migration, inhibitors of
PIM kinases have become a focus for drug discovery research,
including APFO (Blanco-Aparicio and Carnero, 2013). Based on
APFO’s antitumorgenicity profile, a phase 1 trial was sponsored
by CXR Biosciences, Ltd. (2 James Lindsay Pl, Dundee DD1 5JJ,
UK) to determine the safety, dose limiting toxicity, and maxi-
mum tolerated dose (MTD) of APFO.
This phase 1 trial also enabled detailed evaluation of various
clinical chemistries. Observational epidemiologic research has
reported positive associations between measured or modeled
serum PFOA concentrations and higher serum cholesterol
(Nelson et al., 2010; Steenland et al., 2009; Winquist and
Steenland 2014a). These findings, however, are contrary to the
PPARa-mediated lowering of serum lipids that occur in rodents
treated with APFO (Kennedy et al., 2004) as well as the
pharmacodynamics (PD) reduction of serum lipids in humans
mediated by the PPARa agonist fibrate drugs (Roy and Pahan,
2009).
The purpose of this paper is to describe this APFO phase 1
trial and the time-dependent relationships that were observed
over the course of this study between administered doses of
APFO, plasma concentrations of PFOA, and several clinical
markers, including cholesterol, in the participating subjects.
MATERIALS ANDMETHODS
Study Design for Phase 1 Trial of APFO
This open-label, nonrandomized, phase 1 study used a dose-es-
calation design (Le Tourneau et al., 2009). The study was con-
ducted in 2008–2011 at 2 centers in Scotland: Beatson West of
Scotland Cancer Centre (Glasgow) and the Aberdeen Royal
Infirmary. CXR Biosciences (Dundee, Scotland) was the study
sponsor. The study was conducted in accordance with the
International Conference on Harmonization of Good Clinical
Practice and approved by the Glasgow West Research Ethics
Committee. All subjects provided written informed consent
prior to undergoing any study-related procedure.
Subject Eligibility
Patients with histologically or cytologically confirmed advanced
solid tumors, refractory to standard anticancer therapy or for
which no standard therapy existed, were recruited in this study.
Other inclusion criteria for study subjects were:18 years,
physician-assessed life expectancy greater than 3 months, ade-
quate hematologic function, able to comply with study proce-
dures, and written consent. Exclusion criteria included any
anticancer therapy within the last 4 weeks (including chemo-
therapy, radiotherapy, endocrine therapy, immunotherapy, or
use of other investigational agents), HIV infection, hepatitis B or
hepatitis C positivity, inadequate renal function, abnormal liver
function tests, lack of physical integrity of the GI tract that
might lead to impaired administration and absorption of the
oral therapy, and uncontrolled cardiac disease. Ammonium
perfluorooctanoate is a potent inhibitor of CYP2C (Elcombe
et al., 2011); therefore, patients taking warfarin, phenytoin, or
tolbutamide were excluded from the trial.
Pretreatment Evaluation
For each subject, pretreatment evaluations included a full medi-
cal history, tumor evaluation, chest X-ray and 12-lead ECG, full
blood count and coagulation screen, biochemical profile includ-
ing urea, electrolytes, alanine transaminase (ALT), aspartate
transaminase (AST), alkaline phosphatase, bilirubin, total
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cholesterol, low-density lipoprotein (LDL), high-density lipopro-
tein (HDL), triglycerides, albumin, calcium, urea, uric acid, thy-
roid stimulating hormone (TSH), free thyroid hormone (fT4),
blood glucose, urinalysis, and a physical examination.
Trial Treatment
Based on known APFO pharmacokinetics (PKs) in monkeys
(Butenhoff et al., 2004), treatment could be administered orally
via gelatin capsules that would result in the desired plasma
PFOA concentrations. Therefore, the study drug was adminis-
tered in powder-filled hard gelatin capsules containing 50 mg of
APFO. The bulk active pharmaceutical ingredient was manufac-
tured under Good Manufacturing Practices conditions by
Chimete Srl (Tortona, Italy). The capsules were manufactured
according to GMP by Penn Pharmaceutical Services, LTD
(Tredegar, UK).
The pharmacy at each institution controlled the dispensing
of APFO. The administration of APFO to the subject occurred by
authorized staff to ensure treatment compliance. Prophylactic
antiemetics were not administered, and subjects were
requested to fast for 1 h after ingestion of APFO. If a subject
vomited after ingestion of the oral capsule, then the time of the
event was recorded but another capsule was not administered
to replace this administration of APFO. Blood samples for PK
analysis as well as for clinical chemistries were taken over the
following 6-week period. Following this 6-week trial period, the
subjects could continue the treatment with weekly administra-
tion of drug should they so desire in consultation with their
physician. For the purpose of this paper, analyses focus on the
6-week trial period.
Treatment Cohorts
Initial dose cohort. Ammonium perfluorooctanoate was adminis-
tered orally as a single dose of 50 mg in the morning after an
overnight fast in the first cohort of 3 subjects and PK and PD
(PK/PD) parameters were measured over a 6-week period. No
further dosing was given to this cohort during the 6-week
period.
Dose-escalation cohorts. In a 3þ 3 dose-escalation trial design for
a phase 1 clinical trial (Le Tourneau et al., 2009), 3 subjects are
enrolled into a given dose cohort. If there is no dose-limiting
toxicity (DLT) observed among these subjects, the trial proceeds
to enroll additional subjects into the next higher dose cohort. If
DLT occurs in 1 of the 3 subjects within an individual dose co-
hort, then up to 3 more subjects can be treated at this dose level
and dose escalation is only allowed if no further DLT is ob-
served. If DLT occurs in 2 of the 3 subjects within an individual
dose cohort, then no further dose escalation is allowed. The
dose level immediately below the maximum administered dose
is then defined as the MTD. An additional cohort of subjects
could be treated at this MTD up to a total of 12 subjects.
In the dose cohorts that followed the initial dose cohort, sub-
jects were treated with weekly administration of APFO from the
start of dosing. Dose escalation was performed only after the
subjects at the preceding dose level had completed a 3-week re-
peat dosing period. If a subject had not completed 3 weeks of re-
peat dosing with APFO for reasons other than toxicity (eg,
withdrawal of consent), the subject was replaced for the pur-
pose of toxicity evaluation. All subjects who were dosed were
included in this analysis of the data.
In the present study, the dose of APFO was initially doubled
in successive cohorts until agrade 2 drug-related toxicity was
observed. The dose assigned to a specific dose cohort was
reviewed and determined by the investigators and study spon-
sor before any subjects were treated at a new dose level. No
intrasubject dose escalation was allowed.
Subjects were allowed to receive supportive care therapies.
All medications (prescription and over-the-counter) taken dur-
ing the course of the trial were documented. No other chemo-
therapy, immunotherapy, hormonal therapy, radiation therapy,
or other experimental therapies were permitted during the trial.
However, a subject’s clinical needs were paramount, and if a re-
stricted concomitant medication or therapy was required
whereas the subject was enrolled in the trial then this may have
necessitated withdrawal of the subject.
Treatment Discontinuation
Treatment discontinuation was considered in the event of a
subject decision to withdraw consent to further treatment,
treatment-related serious adverse events, recurrent DLT despite
appropriate dose-modifications, progression of the underlying
malignant disease, and if further treatment with APFO was con-
traindicated in the opinion of the investigator.
PK Assessment
For the initial dose cohort who received a single dose (50 mg) of
APFO, PFOA in plasma was measured at predose, and then 0.25,
0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 24, 48, and 72 h after administration and
then once weekly at weeks 2 through 6. For those subjects with
repeat dose administration, blood samples were taken at
predose and then 2, 3, 4, and 24 h after each weekly administra-
tion for 6 weeks. A complete PK assessment is reported else-
where (Campbell et al., in preparation).
Analytical Measurement of PFOA
Details are presented in the Supplementary Data. All analytical
measurements of PFOA were conducted by CXR Biosciences
(Dundee, Scotland). Plasma PFOA was reported in lM (lM
PFOA¼ 413 ng/ml). The method used 40 lL plasma, solvent ex-
traction followed by LC/MS/MS, and provided sufficient detect-
ability (ie, lower limit of quantitation [LLOQ] of 5 ng/ml) to fully
define the PKs following the initial dose. This LLOQ is inappro-
priate for the levels found in general human populations.
However, calibration and quality control standards were ad-
justed as appropriate to cover the range required with increas-
ing dose. Accuracy was within 15% of the actual value and
precision did not exceed 15% of the coefficient of variation at all
concentrations above the LLOQ. The LLOQ was established as
the lowest point on the calibration with accuracy and precision
within 20% limits.
PD Assessment
For those subjects with repeat dose-administration, blood sam-
ples for clinical measures were taken after an overnight fast:
Predose, 2 and 24 h postdose for 6 weeks and analyzed in the
hospital clinical laboratories. Units of reported measurement
were the following serum lipids: total cholesterol, LDL, and
HDL (mmol/l¼ 38.6  mg/dL); serum triglycerides (mmol/l¼
88.5mg/dl); thyroid: TSH (mIU/l) and fT4 (pmol/l¼ 0.08ng/dl);
glucose (mmol/l¼ 18mg/dl); liver and pancreatic enzymes and
bilirubin: ALT, AST, gamma glutamyl transaminase (GGT), alka-
line phosphatase, amylase (IU/l), and total bilirubin (mg/l); liver
function blood clotting tests: Fibrinogen (g/l), prothrombin time
(PTT) (s), activated partial thromboplastin time (aPTT) (s); serum
proteins: total albumin and globulin (mg/dl); and renal clinical
chemistries: serum creatinine (lmol/l¼ 0.0113 mg/dl); urea
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(mmol/l¼BUN [mg/dl]0.3571); and uric acid (lmol/
l¼ 0.0168mg/dl).
Tumor Response
Tumor response was assessed clinically every three weeks and
involved radiologic evaluation of disease at the end of the six-
weeks, as well as for those who requested continued treatment.
Response to APFO treatments was recorded using the RECIST
criteria (Therasse et al., 2000) in subjects with measureable dis-
ease. These tumor response findings are not reported herein.
Statistical Analyses
Internal dosimetry of PFOA, not the dose group, was considered
the most appropriate metric for the evaluation of the clinical
chemistries. The baseline (before first dose) and subsequent 24-
h postdose plasma PFOA and clinical chemistry results (through
the 6 treatments) were considered for statistical analyses and
characterized by estimating the univariate and bivariate distri-
butions, and examining for outliers and other anomalies.
Simple graphic displays were used to characterize these distri-
butions, including box plots and scatter plots. Autocorrelations
and intraclass correlations (ICC) of the time series were esti-
mated and Box-Cox transformations to normalize raw data
were evaluated. To accommodate correlation of values within
subject, generalized estimating equation (GEE) models were fit-
ted to estimate the trends in clinical chemistries over concen-
trations of PFOA.
Combining Toxicologic and Epidemiologic Information
Via an Information Theoretic PK/PD Model
In order to replicate the observed PK/PD, we tested different
metamodels (ie, different models with different parameters or
values of parameters) for which the goal was to reproduce se-
lected observed patterns with the highest accuracy. These pat-
terns were (1) the variation of PFOA over time; (2) the probability
distribution functions (pdf) of PFOA and clinical chemistries
over time; and (3) the patterns of clinical chemistries (eg, total
cholesterol, HDL, triglycerides, TSH, and fT4) conditional on dif-
ferent levels of PFOA. Note that these 3 patterns encompass the
classical PK and PD relationships, better defined as the
concentration-time, effect-time, and effect-concentration rela-
tionships, respectively. The model architecture used for the PK/
PD modeling was the one proposed by Lindhardt and
Gennemark (2014). This model has been implemented in the
‘‘PopED lite’’ computational platform (http://www.bluetree.me/
PopED_lite.html). PopED lite is a computational technology for
clinical PK and PD studies (software and documentation is
found at http://arxiv.org/abs/1505.06658v1). PopED lite focuses
on optimization of the dosage and PK/PD sampling (or
observation) times to improve the accuracy of the parameter
estimates of fixed-effect PK/PD models. Thus, model design
(“metamodeling”; Saltelli et al., 2008) via global sensitivity and
uncertainty analyses (GSUA) in this context refers to the selec-
tion of the optimal probability distribution functions and value
ranges that maximize the accuracy of predicting the three pat-
terns considered. Prediction accuracy is assessed by three accu-
racy indicators: The root mean square error (RMSE), the
Kullback-Leibler divergence over time (KL), and the Akaike
Information Criterion (AIC). These three indicators are deter-
ministic, probabilistic and model validation criteria, respec-
tively, and are calculated for all three patterns considered. An
RMSE is a classical indicator of model performance that
depends on average values of variables; KL is a probabilistic in-
dicator that considers the whole probability distribution of vari-
ables; and AIC is a computational complexity indicator that
considers the number of parameters in the model. The selection
of these evaluation indicators allowed for global assessment of
model performance and determination of its reliability. One ad-
vantage was examination of the sensitivity of the estimated ef-
fect of interest to the distributions underlying the other
parameters in the model. From this there can be an assessment
to what extent the findings can be influenced by the model
form and parameterization. For a more complete development
of the GSUA model (Sobol, 1993; Ludtke et al., 2008) and perti-
nent implementation details, see Supplementary Data.
The PK of the population cohort was modeled by a linear
two-compartment model as (Figure 1)
C0pu ¼
D
V
 ka  ekat  k12  Cpu ðtÞ þ k21  C2ðtÞ  k10  CpuðtÞ (1)
C02ðtÞ ¼ k12  Cpu ðtÞ  k21  C2ðtÞ (2)
where Cpu and C2 represent unbound concentration in the
plasma compartment and in a second tissue compartment, re-
spectively. D is the weekly dose given (zero for the baseline
value) and the parameters V (volume of distribution), ka, k12, k21,
and k10 are calibrated simultaneously in a fitted model that con-
siders the data and aims to maximize multi-pattern prediction
accuracy (see Supplementary Data for details). The PD of the
population cohort of the drug was modeled as follows. A first-
order distribution delay of compound to and from the biophase
(compartment) was assumed to be the rate-limiting step, and
thus requires no assumptions about the timing of response, and
an effect-compartment model was used, where the concentra-
tion in the effect compartment was linked to the plasma com-
partment by a first-order equilibrium rate constant ke. The rate
of change of compound concentration in the effect compart-
ment could then be expressed by
C0eu ðtÞ ¼ ke  ½Cpu ðtÞ  Ceu ðtÞ (3)
where C0eu denotes the unbound effect compartment concentra-
tion (Figure 1). The observed PD effect was modeled by a power
function as
EðtÞ ¼ a Ceu ðtÞb (4)
where E denotes the effect variable (such as total cholesterol
and fT4 but in general could be any clinical chemistry), and a
and b are calibrated input factors whose specific value depends
on the effect compartment but whose probability distribution
does not (see Supplementary Data for details). In this way, we
keep the power exponent b and the scaling factor a as effect-
dependent factors but the structure of the observed PD effect is
invariant, as should be expected. The effect compartment repre-
sents the target site concentration, and is used to infer
concentration-effect relationships (or PD relationships versus
the concentration-time PK relationships) without ambiguity
from variability of delays in effect. The model was calibrated for
1 week and validated for the next 5 weeks of the 6-week phase 1
trial in which the population cohort was studied.
A sensitivity analysis was conducted to determine the influ-
ence of the study subjects’ treatment with cholesterol lowering
drugs, thyroid medications, and corticosteroids.
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RESULTS
Systemic Response
A total of 50 subjects (22 females, 28 males) were initially en-
rolled and 49 underwent the treatment in this phase 1 trial of
APFO (see Table 1). These 49 subjects were on average 61 years
of age, were 1.7 m in height, and weighed 75 kg (Supplementary
Table 1). Estimates of autocorrelation and ICC were small
enough to ignore, thus for the purposes of modeling, all meas-
urements were treated as independent. Supplementary Table 2
provides the distribution of tumor sites and a breakdown of the
colorectal and pancreatic cancers by stage.
No more than one subject showed DLT at any dose so there-
fore the protocol-defined MTD was not reached. The
recommended phase 2 dose (RP2D) of 1000 mg weekly was
based on tolerability of common cumulative drug-related toxic-
ities which consisted primarily of fatigue, nausea, vomiting,
and diarrhea. Stable disease for>12 weeks was observed in
8 subjects including subjects with anaplastic thyroid (40 weeks),
pancreatic (35 weeks), and colon (34 weeks) cancer (MacPherson
et al., 2011).
Plasma PFOA Concentrations
The trajectory of both observed and modeled plasma concentra-
tions of PFOA over time for different dose groups are provided
in Figure 2. The plot shows that, although cumulative dose goes
up linearly, plasma concentration begins to plateau with in-
creasing dose categories. The highest dose category showed a
plateau at around 600 h into the dosing period.
PK/PD Modeling
The two clinical chemistry measures that showed clearly ob-
servable associations with PFOA concentrations were total cho-
lesterol and fT4.
Based on the GEE analysis for total cholesterol (Figure 3), the
average rate of change in total cholesterol with increased PFOA
concentration was approximately 1.2 103 mmol/l/lM
(Figure 3).
Table 1. Treatment Data for the 49 Subjects in the Phase 1 Clinical Trial
APFO Dose (mg) Number of Subjects 6 Weeks (wks) of Treatment (Yes/No)
Initial single dose cohort 50 3 (Single dose week 1 only)
Repeat weekly dose cohorts 50 1 Yes¼ 1; No¼ 0
100 3 Yes¼ 2; No¼ 1 (missed wks 5–6)
200 3 Yes¼ 3; No¼ 0
300 4 Yes¼ 2; No¼ 2 (1 missed wk 6; 1 missed wks 2–6
450 3 Yes¼ 2; No¼ 1 (missed wk 6)
600 7 Yes¼ 4; No¼ 3 (1 missed wk 5; 2 missed wks 4–6)
750 3 Yes¼ 2; No¼ 1 (missed wk 6)
950 4 Yes¼ 2; No¼ 2 (1 missed wk 6; 1 missed wks 2–6)
1000 12 Yes¼ 7; No¼ 5 (1 missed wk 4; 1 missed wk 5;
1 missed wk 3 and wk 6; 2 missed wks 4–6)
1200 6 Yes¼ 2; No¼ 4 (1 missed wk 4; 1 missed wks 5–6;
2 missed wk 6)
Figure 2. Observed and predicted plasma concentration of PFOA over time con-
ditional on the assigned dose. Predictions and data are solid and dashed lines as
a function of dose category. The PK/PD model predictions are shown only for the
lowest and highest dose category. Variability around PK curves is a function
of the pdf assigned to the input factors and numerical Monte Carlo variability
related to the Sobol sampling scheme.
Figure 1. Conceptual diagram of the PK/PD compartmental model. The black
and red boxes refer to the stochastic pharmacokinetic (PK) and pharmacody-
namics (PDs) model, respectively. Dose of the drug, plasma concentration, un-
bound concentration in the tissue and effect in the biologic compartments are
the quantities that are calculated by the model. Cpu and C2 represent unbound
concentration in the plasma compartment and in a second tissue compartment.
The parameters V, ka, k12, k21, and k10 are calibrated simultaneously in a fitting
model that considers the data and aim to maximize prediction accuracy. The
concentration in the effect compartment was linked to the plasma compart-
ment by a first-order equilibrium rate constant ke. Ceu denotes the unbound ef-
fect compartment concentration. E denotes the effect variable, and a and b (see
equation 4) are calibrated input factors whose specific value depends on the ef-
fect compartment (or clinical biomarker) but their probability distribution does
not. i and j refer to any clinical biomarker that are mutually dependent.
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There was a clear transition in shape and range of the pdf for a
decrease in total cholesterol (Figs. 4 and 5) that occurred at roughly
PFOA levels between 420 and 565lM (approximately 175 000–
230 000 ng/ml). This transition is manifested by the maximum
value of the KL divergence quantified between pdfs of all PFOA
categories. These PFOA concentrations are several orders of mag-
nitude higher than reported in workers or the general population.
Figure 6 displays pdf results for total cholesterol, HDL, and LDL
demonstrating that the impact of PFOA was on decreased LDL but
not HDL. In addition, the variability of total cholesterol was higher
at lower PFOA levels. The higher dosed subjects experienced a rel-
atively narrower range of total cholesterol values but much higher
variability in PFOA plasma concentration. Supplementary Figure 1
demonstrates the same results for subjects grouped in 3 different
treatment bins used to calculate the average value of total choles-
terol, verifying the robustness of these analyses.
Based on the GEE analysis for fT4 (Figure 7), the average rate
of change in fT4 was 2.8 103 pmol/l/lM with a transition in
shape and range of the pdf at higher concentrations of PFOA
(Figure 8) than seen with cholesterol. This transition is mani-
fested by the maximum value of the KL divergence quantified
between pdfs of all PFOA categories. In Figure 9, which graphs
both TSH and fT4 pdf as a function of PFOA plasma concentra-
tion, it is clear that only fT4 was influenced (increased) by PFOA,
not TSH. Compared with cholesterol, the distribution of fT4
appeared not to narrow with increasing PFOA level.
Supplementary Figure 1 also presents the fT4 results with sub-
jects grouped by the three treatment bins.
Based on the analysis of the PK/PD model, the average rate
of decrease in total cholesterol and increase of free T4 associ-
ated with increasing PFOA were approximately
0.30 102 mmol/l/lM and 2.66103 pmol/l/lM, respectively;
Figure 3. Generalized estimating equations analysis of cholesterol and PFOA. Slope and 95% CI presented. Dots of different colors are for different dose groups.
Figure 4. Observed and predicted probability distribution function of cholesterol and dependent on PFOA concentration. (Left) The solid pdfs are cholesterol levels for
the lowest and highest PFOA concentration categories predicted by repeated runs of the PK/PD model whereas the dashed pdf are from smoothed observations. (Right)
Box plots and slope of the observed and slope of the model-predicted average value of cholesterol plotted as a function of each of the 10 PFOA serum concentration cat-
egories. The black and red bars in the boxes represent the median and the mean value respectively. Dots above boxes are outliers (upper dots are more than 3/2 times
of upper quartile, whereas lower dots are less than 3/2 times of lower quartile). The extremes of the whiskers are the maximum and minimum values for each category
excluding outliers. The extremes of the boxes are the third and first quartiles.
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thus, the GEE underestimates the change of cholesterol, but pre-
dicts relatively correctly the change in fT4. Note that the change
in fT4 was not as nonlinear as the change in cholesterol consid-
ering the pdfs of these biomarkers. Despite the largest change is
observed for cholesterol (probabilistically speaking), the change
in the average value (explained linearly) is small, and smaller
than the average change of fT4, despite the latter is changing
less than cholesterol probabilistically. This is clearly related to
the nonlinear dynamics where seemingly small changes in av-
erage values actually produce large effects.
Figures 10 and 11 present pdfs for ALT and serum creatinine,
respectively, by plasma PFOA group. Both clinical chemistries
did not show appreciable changes as a function of PFOA levels.
It is possible that serum creatinine was higher for a few individ-
uals for highest values of PFOA, but there is little evidence of
any impact on ALT.
The dynamics of other clinical measures—triglycerides, urea,
glucose, AST, GGT, alkaline phosphatase, total bilirubin, fibrino-
gen, PTT, and aPTT—show almost no observable differences with
measured plasma PFOA concentrations (Supplementary Figs. 2–6).
Sensitivity analyses displays the results for cholesterol and
fT4 robust to subject treatment with statins (n¼ 6 subjects), thy-
roxine (n¼ 3 subjects), and corticosteroids (n¼ 18 subjects).
(Supplementary Figs. 7–10).
The most important result of GSUA performed for the sto-
chastic PK/PD model showed the relative importance between
compartment effects factors and dose-plasma factors
(Supplementary Figs. 11–13). Details of these analyses are given
in the Supplementary Data. Viewed from the perspective of the
plasma concentration, the factor D is the most important driver
of the whole model. The second most important factors are a, b,
and ke, which determine the PD response, our main interest
here. For each of these factors, the dependence on other factors
is balanced by their independent impact. Although somewhat
dependent on other factors, these estimates are generally ro-
bust. Non-negligible, particularly in terms of model factor inter-
actions are the plasma-compartment factors k12, k21, and k10.
In other words, the way in which the drug is assimilated by
each model compartment is important to the concentration.
The volume V and the absorption rate ka did not seem to deter-
mine significantly the PK/PD dynamics.
DISCUSSION
PFOA and Lipid Dynamics
The plasma PFOA concentrations measured in this phase 1
study are the highest ever reported in humans. At plasma PFOA
concentrations between 420 and 565 lM (approximately
175 000–230 000 ng/ml), there was a marked decrease in serum
total cholesterol but not in HDL. This reduction in non-HDL cho-
lesterol is consistent with the known PDs of PPARa agonists
used to treat hyperlipidemia in humans. For example, the
fibrate drugs (eg, clofibrate), work through the regulation of
genes involved in lipid metabolism (Roy and Pahan, 2009). PFOA
activates human PPARa both in vitro in primary hepatocytes
(Bjork and Wallace, 2009) and in vivo in humanized PPARa mice
(Albrecht et al., 2013).
The phase 1 results are generally consistent with the
toxicologic evidence, where PFOA has been shown to activate
PPARa and regulate the transcription of genes involved with
lipid metabolism in rats and mice (Albrecht et al., 2013; Elcombe
et al., 2010). Rodents treated with APFO over 14 days showed
Figure 5. Probability distribution functions of total cholesterol over increasing PFOA concentrations for all subjects in the cohort. The colors of the pdf correspond to
the PFOA concentrations groups as in the legend.
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decreased serum lipids at PFOA levels between 20 000 and
51 000 ng/ml in rats and 10 000–14 000 ng/ml in mice (Loveless
et al., 2006). A study of C57BL/6 and BALB/c mice fed a high cho-
lesterol and fat diet containing PFOA, found elevated hypercho-
lesterolemia (primarily HDL) (Rebholz et al., 2016) but this was
not supported by a study of humanized ApoE*3.Leiden.CETP
mice (Westerterp et al., 2006), in which a Western diet contain-
ing APFO resulted in decreased plasma non-HDL cholesterol
and triglycerides (Princen et al., 2016). Hypolipidemia was not
observed in cynomolgus monkeys with repeated oral
administration of APFO over six months (Butenhoff et al., 2002).
Human PPARa receptors have comparable affinity to PPARa ago-
nists (Corton et al., 2014), but less than 10% the level of PPARa
receptors compared with rats and mice (Gonzalez et al., 1998). It
is, therefore, reasonable to conclude that the hypolipidemic re-
sponse observed in the phase 1 trial subjects may be consistent
with a PPARa-mediated mode of action.
Several observational epidemiologic cross-sectional studies
of general populations have reported positive associations be-
tween serum cholesterol (primarily LDL) and PFOA (Eriksen
et al., 2013; Geiger et al., 2014; Nelson et al., 2010; Starling et al.,
2014) at approximately 4 orders of magnitude lower concentra-
tions than in this phase 1 study. Furthermore, the modest asso-
ciation observed in studies of general populations is
inconsistent with the weaker associations reported in more
highly exposed workers (Costa et al., 2009; Olsen and Zobel,
2007; Sakr et al., 2007a,b; Steenland et al., 2010a, 2015). An associ-
ation between high cholesterol and measured PFOA (Fitz-Simon
et al., 2013; Frisbee et al., 2010; Steenland et al., 2009) and model-
derived cumulative PFOA (Winquist and Steenland 2014a) has
been reported in a mid-Ohio river valley community whose
drinking water contained PFOA from a nearby fluoropolymer
plant. However, there was no increased risk for coronary artery
disease related to PFOA exposure in this population. The C8
Science Panel (2012a) considered the observed increased risk for
high cholesterol with exposure to PFOA small in magnitude and
would therefore not necessarily result in increased heart dis-
ease given its other attributable risk factors. Studies of highly
exposed PFOA occupational cohorts have also not reported in-
creased risks with either coronary artery disease incidence
(Steenland et al., 2015) or mortality (Raleigh et al., 2014;
Steenland and Woskie, 2012) when using internal referent com-
parisons to minimize confounding by nonrepresentative gen-
eral referent populations.
Because of the consistency from this phase 1 trial and
toxicologic studies demonstrating lower cholesterol with high
concentrations of PFOA, on the one hand, and the inconsistency
with the observational epidemiologic associations showing
higher cholesterol with markedly lower PFOA concentrations on
the other, future research should address noncausal biologic
explanations for the latter. Several possibilities include:
1. Inherent variability in the glomerular filtration rate (GFR),
which confounds other associations reported with PFOA, in-
cluding lower birthweight (Verner et al., 2015) and chronic
Figure 6. Observed probability distribution function of cholesterol. Total choles-
terol, HDL, and LDL are considered. HDL is invariant for any PFOA class, and by
LDL that is decreasing for increasing values of PFOA. The pdfs of cholesterol for
the lowest and highest PFOA plasma classes are shown with a thick line to em-
phasize the change in their probabilistic structure. Pdfs of different colors corre-
spond to the PFOA concentration groups as in the legend.
Figure 7. GEE analysis of fT4 and PFOA. Slope and 95% CI presented. Dots of different colors are for different dose groups.
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kidney disease (Watkins et al., 2013). Studies have shown
that individuals with dyslipidemia, as well as those taking a
much less aggressive atorvastatin treatment for their dysli-
pidemia, have lower GFR (Lin et al., 2015; Shepherd et al.,
2007). These studies may suggest that elevated cholesterol
may affect GFR which may then result in increased retention
of PFOA.
2. Organic anion transporters in the gastrointestinal tract and
liver that may share binding affinity with lipids and PFOA,
analogous to the URATE transporter in the proximal tubule
and uric acid and PFOA (Han et al., 2012). Organic anion
transporting polypeptides in human and rodent hepato-
cytes and enterocytes have been shown to transport PFOA,
thus contributing to its enterohepatic circulation (Zhao
et al., 2017). Thus, persons with increased enterohepatic cir-
culation transport of lipids may also have increased reten-
tion of PFOA.
3. Saturation in an underlying physiologic mechanism given
the nonlinear association between PFOA and cholesterol, as
was suggested by Steenland et al. (2009) and Frisbee et al.
(2010). This could involve reabsorption at the proximal tu-
bule and/or enterohepatic reuptake.
4. Lipoproteins that may bind with PFOA, but this is less plau-
sible since 99% of the PFOA in one human donor sample was
distributed in lipoprotein-depleted plasma (Butenhoff et al.,
2012b). Additional study subjects would be reassuring to as-
sess this result.
Plausible biologic modes of action that support the hyper-
cholesterolemia positive association reported at low ng/ml
PFOA concentrations, whereas explaining negative association
Figure 8. Observed and predicted probability distribution function of fT4 and dependent on PFOA concentration. (Left) The solid pdfs are fT4 levels for the lowest and
highest PFOA concentration categories predicted by repeated runs of the PK/PD model whereas the dashed pdf are from smoothed observations. (Right) Box plots and
slope of the observed and slope of the model-predicted average value of fT4 plotted as a function of each of the 10 PFOA serum concentration categories. The black and
red bars in the boxes represent the median and the mean value respectively. Dots above boxes are outliers (upper dots are more than 3/2 times of upper quartile,
whereas lower dots are less than 3/2 times of lower quartile). The extremes of the whiskers are the maximum and minimum values for each category excluding out-
liers. The extremes of the boxes are the third and first quartiles.
Figure 9. Observed probability distribution function of thyroid function. TSH is
invariant and fT4 is higher for higher values of PFOA. The pdfs of fT4 for the low-
est and highest PFOA plasma classes are shown with a thick line to emphasize
the change in their probabilistic structure. Pdfs of different colors correspond to
the PFOA concentration groups as in the legend.
Figure 10. Observed probability distribution function of ALT. ALT is invariant for
any PFOA categorization. Pdfs of different colors correspond to the PFOA con-
centration groups as in the legend.
Figure 11. Observed probability distribution function of serum creatinine.
Serum creatinine appears to be slightly increasing for increasing values of PFOA
but this was based on one individual. Pdfs of different colors correspond to the
PFOA concentration groups as in the legend.
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at high concentrations, also need to be investigated. Serum
PFOA concentrations as low as 50 ng/ml have not resulted in
higher cholesterol levels in humanized ApoE*3.Leiden.CETP
mice given the reduction in cholesterol at higher PFOA concen-
trations (personal communication H Princen, TNO Biosciences).
Therefore, there needs to be a concerted effort to focus on
modes of action to address the existence of a PFOA-mediated ef-
fect with the positive cholesterol associations reported in obser-
vational epidemiologic studies.
PFOA and Thyroid Function
The observed increase in fT4 seen in this phase 1 trial, with no
apparent effect on TSH, suggested that the increase in fT4 was
not clinically significant but may be due to displacement of the
thyroid bound hormone by PFOA. These findings appear similar
to the toxicologic evidence in laboratory studies with perfluor-
ooctanesulfonate (PFOS), which displaced thyroxine from bind-
ing proteins in rats, transiently increasing free thyroxine
without altering overall thyroid hormone homeostasis (Chang
et al., 2007, 2008; Weiss et al., 2009). PFOA is structurally similar
to PFOS in that both compounds resemble a fatty acid in their
amphiphilic nature and compete for binding with free fatty
acids on albumin and liver fatty-acid binding protein (Luebker
et al., 2002), and therefore, PFOA can also similarly displace thyrox-
ine (Butenhoff et al., 2012c). Such displacement has been shown
with aspirin, heparin, and free fatty acids (Koulouri et al., 2013).
Analogous to the cholesterol studies mentioned above, stud-
ies of thyroid hormone measurements and thyroid diseases can
be categorized into: (1) general populations for which many
have been cross-sectional (eg, Melzer et al., 2010; Wang et al.,
2013; Webster et al., 2016; Wen et al., 2013); (2) the mid-Ohio river
valley community (Knox et al., 2011; Lopez-Espinosa et al., 2012;
Winquist and Steenland 2014b), and (3) occupational studies
(Costa et al., 2009; Olsen and Zobel, 2007; Sakr et al., 2007a,b;
Steenland et al., 2015). The studies of general populations did
not yield consistent results with measured thyroid hormones
and could be subject to reverse causation (Webster et al., 2016)
as GFR will decrease in the untreated or subclinical hypothyroid
state and increase in the untreated hyperthyroid or subclinical
state, both of which can be normalized upon treatment
(Dousdampanis et al., 2014; Koulouri et al., 2013; Woodward
et al., 2008). Such an effect on GFR may retain or eliminate un-
bound PFOA, respectively. In the mid-Ohio river valley studies,
PFOA exposure was measured in cross-sectional studies (Knox
et al., 2011; Lopez-Espinosa et al., 2012) and estimated via expo-
sure models in a longitudinal study of a community with diag-
nosed functional thyroid disease (Winquist and Steenland
2014b). The latter study reported associations for women diag-
nosed mainly with hyperthyroidism and for men with hypothy-
roidism. Occupational studies that have measured thyroid
hormones did not report consistent associations with thyroid
hormones nor did they provide workers’ thyroid disease histo-
ries, except for a prospective study (Steenland et al., 2015) that
reported an exposure trend with PFOA for hypothyroidism in
male workers.
PFOA and Liver Enzymes and Function
During this 6-week phase 1 trial, ALT and all other liver
enzymes appeared unaffected by plasma concentrations of
PFOA up to 1530 lM. Nor did it appear hepatic functional
changes were altered as analyzed by fibrinogen, PTT, and aPTT.
In rats and mice treated with APFO, liver effects such as in-
creased serum ALT and AST values (Butenhoff et al., 2012a;
Minata et al., 2010; Son et al., 2008); peroxisome proliferation
with subsequent hepatocellular hypertrophy (Elcombe et al.,
2010; Haughom and Spydevold, 1992; Loveless et al., 2006;); and
increased incidence of hepatocellular adenoma in rats (Biegel
et al., 2001; Butenhoff et al., 2012a) were reported, but these
changes were attributed to PPARa activation, a mode of action
unlikely to result in human liver tumors (Corton et al., 2014; Das
et al., 2017). An increased liver weight reported in an APFO feed-
ing study of monkeys was due, in part, to adaptive hepatocellu-
lar hypertrophy possibly as a result of mitochondrial
proliferation (Butenhoff et al., 2002); no corroborative changes in
either serum ALT or alkaline phosphatase occurred. Studies of
the mid-Ohio river valley community reported small shifts in
liver enzymes with increasing PFOA (Darrow et al., 2016; Gallo
et al., 2012). The C8 Science Panel (2012b) considered this within
normal physiologic ranges and found other study population
results inconsistent; thus, they were uncertain whether PFOA
was the cause of these modest liver enzyme associations but
this did not reflect in any increased risk in liver disease, includ-
ing medically validated enlarged liver, fatty liver, or cirrhosis.
PFOA and Kidney Function
Serum creatinine, urea, and uric acid were not associated with
the PFOA concentrations in this phase 1 trial. Two-year bioas-
says in rats (Biegel et al., 2001; Butenhoff et al., 2012a) and a 6-
month study in monkeys (Butenhoff et al., 2002) did not find
treatment-related renal effects with APFO. Epidemiologic cross-
sectional studies have associated chronic kidney disease in chil-
dren and adults with PFOA (Kataria et al., 2015; Shankar et al.,
2011a) or with hyperuricemia (Geiger et al., 2013; Shankar 2011b;
Steenland et al., 2010b); however, these findings were likely con-
founded by the GFR (Watkins et al., 2013; Dhingra et al., 2017).
Dhingra et al. (2016) reported the mid-Ohio river valley popula-
tion was not at an increased risk from chronic kidney disease
based on their community worker longitudinal study of mod-
eled cumulative serum PFOA concentrations.
PK/PD Modeling
Individual response is the result of a complex interaction of ex-
posure and biology and it is very difficult to untangle the causal
effects (via dependent clinical measures) of an exposure unless
they are considered altogether systemically. The novelty of the
PK/PD model is the information theoretic GSUA-driven model
design and evaluation approach. This approach, incorporating
stochastic parameters and state variables, optimizes the trade-
off between model complexity, uncertainty, and relevance.
Nonlinearity is assessed by considering all pdfs of model input
factors and their interdependencies for multiple predicted pat-
terns, interdependencies that are usually neglected.
Optimization is achieved by minimizing three independent
evaluation criteria (RMSE, KL, and AIC). This modeling approach
addresses the uncertainty of data and extends the observed and
discrete biologic dynamics to a continuous domain. Hence, the
model itself also evaluates the consistency and reliability of the
data. Additionally, it helps to identify transition ranges and pre-
dict unobserved exposure dynamics.
Study Limitations
The main limitation of the study is that it used as subjects late-
stage cancer patients whose metabolic activity may differ con-
siderably from healthy individuals. Although there is no evi-
dence that any of the cancers involved or treatments received
prior to the study had systematic effects on the metabolic func-
tions studied, it cannot be asserted with absolute confidence
that no such systematic effects existed.
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The sample size and study length is limited, but the observa-
tion of impacts on two clinical chemistries (total cholesterol
and fT4) suggests that this limitation is not absolute. It may be
that other chemistries were affected, but the power of the study
design was inadequate to detect the effects. Although subjects
were not selected randomly for inclusion in dose groups, but
were taken serially over time, this limitation leading to system-
atic bias by group would depend upon mechanisms not appar-
ent to the investigators. In addition, changes over time within
individuals are consistent with changes seen in the population
averages and pdfs.
Another limitation as it applies to the epidemiologic general-
ization of the results is that much lower serum PFOA concentra-
tions, as previously reported in workers, communities affected
through PFOA-containing drinking water, and general popula-
tions, were not studied. Very low doses having opposite effects
on cholesterol, such that increases in cholesterol are seen for
PFOA concentrations that are orders of magnitude smaller than
those doses administered to these cancer patients, is perhaps
plausible. However, we have not uncovered research identifying
such a mechanism in humans.
CONCLUSIONS
Health concerns about the low levels of PFOA in the environ-
ment have been raised by observational studies. Using data
from this phase 1 study of PFOA, we addressed the effects of ex-
posure to a very wide range of PFOA, including extremely high
PFOA concentrations. For levels of PFOA more than four orders
of magnitude higher than the levels observed in general popula-
tions, there was no evidence of any major effects other than a
decrease in total cholesterol (but not HDL) and an increase in
fT4 (but not TSH) for increasing levels of PFOA plasma concen-
tration. These nonlinear effects that show changes into the
probability distribution of cholesterol and fT4 are evidence for
the importance of probabilistic versus linear models. Our find-
ings are consistent with animal models and may contribute to
focusing the evaluation of human health risks of PFOA in the
environment, by motivating re-examination of the implications
of population studies exposed to much lower levels of PFOA.
These observational studies have reported contrary associa-
tions, but currently understood biology does not support the ex-
istence of such conflicting effects.
SUPPLEMENTARY DATA
Supplementary data are available at Toxicological Sciences online.
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